Canagliflozin Reduces Cardiorenal Biomarkers in T2D
WEDNESDAY, Aug. 23, 2023 (HealthDay News) — For people with type 2 diabetes and albuminuria, canagliflozin reduces the longitudinal trajectory of increase in cardiorenal biomarkers, according to a study published online Aug. 22 in Circulation.James L…
Learn MoreU.S. Gender-Affirming Surgeries Nearly Tripled in 3 Years
WEDNESDAY, Aug. 23, 2023 (HealthDay News) — The number of Americans undergoing gender-affirming surgery is on the rise, new research reveals, almost tripling between 2016 and 2019 alone.During that period, more than 48,000 patients — about half of t…
Learn MoreAHA News: Promotores Create a Bridge Between Healthier Living and a Growing Hispanic Population
WEDNESDAY, Aug. 23, 2023 (American Heart Association News) — Patricia Guevara enjoys doing things with her 5-year-old daughter, Miranda, especially painting and drawing and taking an occasional walk in the park.After a promotora, or community health …
Learn MoreAHA News: A Lifetime of Challenges – Including a Spinal Stroke – Leads Dancer to Infinite Possibilities
WEDNESDAY, Aug. 23, 2023 (American Heart Association News) — As a Japanese American girl growing up in Irvine, California, Marisa Hamamoto felt like an outsider in her predominantly white community. Her schoolmates picked on her because she looked di…
Learn MoreHeterogeneity Found in Appropriate Use Criteria for Imaging of CAD
WEDNESDAY, Aug. 23, 2023 (HealthDay News) — U.S. Centers for Medicare & Medicaid Services (CMS)-qualified Appropriate Use Criteria (AUC) for imaging of coronary artery disease (CAD) are heterogeneous and discrepant, according to a study published onl…
Learn MoreEASD: Factors Linked to Lower-Limb Amputation ID’d in Diabetes
WEDNESDAY, Aug. 23, 2023 (HealthDay News) — For people with newly diagnosed diabetes, the risk for lower-limb amputation (LLA) is increased for those with older age, males, and divorced individuals, according to a study to be presented at the annual …
Learn MoreNivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
WEDNESDAY, Aug. 23, 2023 (HealthDay News) — For patients with metastatic melanoma who receive frontline anti-programmed death protein 1 (PD-1) or therapy against programmed cell death 1 ligand 1 and whose tumors progressed with cytotoxic T-lymphocyte…
Learn More